Standardised training for reducing peritoneal dialysis-related infection: a cluster randomised controlled study Authors: Josephine SF. Chow, Neil Boudville, Suetonia Green, Yeoungjee Cho, Gabor Mihala, Jessica Kasza, Ruth Campbell, Hayley Candler, Carmel M. Hawley, Laura E. Hickey, Charani Kiriwandeniya, Misa Matsuyama, Ramya Movva, Elaine M. Pascoe, Donna M. Reidlinger, Andrea Valks, Pushparaj Velayudham, Liza Vergara, Carolyn Armstrong, Bernadette Buisman, Keri-Lu Equinox, Ana E. Figueiredo, Trudi Fuge, Rachel Haselden, Ashik Hayat, Kirsten Howard, Martin Howell, Allison Jaure, Matthew D. Jose, Anna Lee, Susana San Miguel, Jo-Anne Moodie, Thu T. Nguyen, Walaa WM. Saweirs, Genevieve Z. Steiner-Lim, Melinda Tomlins, Megan Upjohn, David Voss, Rachael C. Walker, David W. Johnson Published: 2026 ABSTRACT SummaryBackgroundPeritoneal dialysis is a widely used treatment for kidney failure; however, peritoneal dialysis-related infections (exit-site, tunnel infection, peritonitis) occur frequently. The effect of standardised nurse and patient training on peritoneal dialysis infections is uncertain. The aim of this study was to determine whether implementing an international guideline-based standardised training curriculum for nurse trainers and new peritoneal dialysis patients reduces the risk of peritoneal dialysis-related infections compared with existing local training practices.MethodsTargeted Education ApproaCH to improve Peritoneal Dialysis (TEACH-PD) was a pragmatic, investigator-initiated, cluster-randomised controlled trial conducted in Australia and New Zealand. Adult patients 18 years of age or older with kidney failure who required training for incident peritoneal dialysis treatment and who were able to provide written informed consent were eligible. Clusters were randomised 1:1 to either the standardised training curriculum or usual care. Participant data and infection outcomes were routinely collected in national patient registries. The primary outcome was time to first peritoneal dialysis-related infection (exit site infection, tunnel infection, or peritonitis). Secondary outcomes were the first of each individual infection type in the primary composite outcome, catheter removal, haemodialysis transfer, all-cause death and quality of life. This trial was registered with ClinicalTrials.gov, number NCT03816111.FindingsBetween 22 July 2019 and 29 September 2023, 42 clusters were randomised: 21 to the standardised training group and 21 to the usual care group. Overall, 1462 incident peritoneal dialysis patients were included; 667 were assigned to the standardised training group and 795 to the usual care group. A peritoneal dialysis-related infection occurred in 296 of 667 patients in the standardised training group and 297 of 795 patients in the usual care group (sub-hazard ratio 1.230, 95% confidence interval [CI] 1.004–1.507, p = 0.0457). Secondary outcomes were similar in the two groups.InterpretationAmong patients commencing peritoneal dialysis, the use of a standardised training curriculum for nurses and patients based on the International Society for Peritoneal Dialysis guidelines increased peritoneal dialysis-related infection. Implementation-focused research is needed to identify which elements of training require standardisation and where individualisation is most beneficial to support safe, sustainable and patient-centred peritoneal dialysis care.FundingThe TEACH-PD trial is funded by MRFF Clinical Trials Activity: Rare Cancers, Rare Diseases and Unmet Need Grant Opportunity; National Health & Medical Research Council BEAT-CKD Program Grant; Health Research Council of New Zealand grant; Metro South Health Research Support Scheme Research Fund—Health System and Health Economics Project Grant; Queensland Health; South Western Sydney Research Small Grant Scheme; International Society for Peritoneal Dialysis; Translational Research Institute Australia; Amgen and Baxter Healthcare (Vantive). Research in contextEvidence before this studyPeritoneal dialysis (PD) is a home-based, cost-effective, kidney replacement therapy, however, PD-related infections remain common worldwide and drive mortality, unplanned hospitalisation, transfer to haemodialysis, and higher healthcare costs. Search in MEDLINE, Embase, and CINAHL from database inception to 1 December 2025 using keywords including “peritoneal dialysis,” “training,” and “infection,” limited to English-language publications, showed that PD-related infections remain common despite predominantly observational evidence with heterogeneous designs, variable training practices, and inconsistent associations between training approaches and infection outcomes. Although international guidelines offer general recommendations, persistent global PD-related infection rates and practice heterogeneity highlight a critical lack of high-quality evidence on optimal PD training methods, supporting the need to evaluate a standardised training intervention.Added value of this studyThis study provides high-quality evidence from a cluster-randomised controlled trial evaluating a standardised, incident PD training curriculum. By rigorously testing training standardisation at scale, our findings challenge prevailing assumptions that uniform training alone reduces infection risk and refine current understanding of the relationship between training methods and PD-related infections.Implications of all the available evidenceCombined with existing literature, these findings suggest that standardising of incident PD training alone is insufficient to reliably reduce infection risk. For practice and policy, this underscores the importance of moving beyond uniform curricula towards training models that are responsive to local context, workforce capability, and patient needs. Further research should prioritise implementation-focused studies to identify which components of training, delivery processes, and contextual factors most strongly influence infection outcomes, thereby informing more effective and scalable approaches to PD training. Research in context Evidence before this study Peritoneal dialysis (PD) is a home-based, cost-effective, kidney replacement therapy, however, PD-related infections remain common worldwide and drive mortality, unplanned hospitalisation, transfer to haemodialysis, and higher healthcare costs. Search in MEDLINE, Embase, and CINAHL from database inception to 1 December 2025 using keywords including “peritoneal dialysis,” “training,” and “infection,” limited to English-language publications, showed that PD-related infections remain common despite predominantly observational evidence with heterogeneous designs, variable training practices, and inconsistent associations between training approaches and infection outcomes. Although international guidelines offer general recommendations, persistent global PD-related infection rates and practice heterogeneity highlight a critical lack of high-quality evidence on optimal PD training methods, supporting the need to evaluate a standardised training intervention. Added value of this study This study provides high-quality evidence from a cluster-randomised controlled trial evaluating a standardised, incident PD training curriculum. By rigorously testing training standardisation at scale, our findings challenge prevailing assumptions that uniform training alone reduces infection risk and refine current understanding of the relationship between training methods and PD-related infections. Implications of all the available evidence Combined with existing literature, these findings suggest that standardising of incident PD training alone is insufficient to reliably reduce infection risk. For practice and policy, this underscores the importance of moving beyond uniform curricula towards training models that are responsive to local context, workforce capability, and patient needs. Further research should prioritise implementation-focused studies to identify which components of training, delivery processes, and contextual factors most strongly influence infection outcomes, thereby informing more effective and scalable approaches to PD training. Introduction Kidney failure is a life-threatening condition that is treated with kidney replacement therapy including kidney transplantation, haemodialysis, and peritoneal dialysis.1,2 In 2023, 4.59 million people were treated with kidney replacement therapy, approximately 11% of whom received peritoneal dialysis.3 Peritoneal dialysis provides home-based therapy, increased life participation, and is cost-effective compared to haemodialysis.4 Peritoneal dialysis has also been identified as a vitally important lever for closing the gap between people with kidney failure who need kidney replacement therapy and those who are able to receive it, particularly in resource-limited settings.5,6 Despite these advantages, peritoneal dialysis-related infections, including exit-site infections, tunnel infections, and peritonitis, remain common worldwide and are a leading cause of technique failure. These infections substantially increase the risks of mortality, unplanned hospitalisation, transfer to haemodialysis, and higher healthcare costs, underscoring the global need for improved and standardised training approaches. Most patients commencing peritoneal dialysis undergo training in the dialysis procedure by trained healthcare professionals to enable their independent treatment at home. However, the evidence regarding how, how long, when, where, or by whom patients should be trained in peritoneal dialysis remains uncertain.7, 8, 9 The International Society for Peritoneal Dialysis (ISPD) Clinical Practice Guidelines recommend specific training approaches for nurse trainers and patients. Variations in training practices and infection rates across clinical settings have led to the hypothesis that standardised training approaches for peritoneal dialysis might reduce peritoneal-dialysis related infections. The aim of the Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes (TEACH-PD) trial was to determine whether implementing a guideline-based standardised training curriculum for nurse trainers and new peritoneal dialysis (PD) patients reduces the risk of PD-related infections (exit site infection, tunnel infection, or peritonitis) compared with existing local training practices. Methods Study design and oversight The Australasian Kidney Trials Network conducted this pragmatic, investigator-initiated, binational, two-arm, parallel-group, open-label, multicentre, registry-based, cluster-randomised, controlled trial in Australia and New Zealand. This was an open-label trial with blinded outcome assessors. The trial protocol and statistical analysis plan were published prior to conclusion of enrolment and data lock for the final analysis, respectively.10,11 The trial was registered at ClinicalTrials.gov (NCT03816111) before initiation and was overseen by an independent data and safety monitoring board (DSMB). The DSMB was responsible to oversee participant safety, monitor accumulating study data, and review trial conduct, including adverse events and interim analyses to ensure the integrity of the study. The DSMB met twice per year and was responsible for making recommendations regarding continuation, modification, or early termination of this study based on safety or efficacy signals. Participants The trial was conducted at 42 peritoneal dialysis training centres across Australia and New Zealand. Centres that had trained 10 or more incident peritoneal dialysis patients in the 2 years before study start (or projected to train ten or more in the 2 years following trial commencement) were eligible. Adult patients 18 years of age or older with kidney failure who required training for incident peritoneal dialysis treatment and who were able to provide written informed consent were eligible. Patients were excluded if they had previously been trained in peritoneal dialysis. Training involving or primarily undertaken by a caregiver was not an exclusion criterion. Randomisation Dialysis centres were randomly assigned in a 1:1 ratio to either an ISPD clinical practice guideline-based standardised training curriculum for trainers and patients (Standardised Training; intervention) or usual training practices (Usual Care; control; Fig. 1). Randomisation and assignment to study groups were set up by an independent, unblinded statistician, and performed using a computer-generated algorithm with block sizes of two (size and schedule concealed until final data lock), and stratified by country and cluster size category (small: <16 incident peritoneal dialysis patients per year, medium: 16–40, large: 41–70, and very large: >70), based on 2019–21 Australian and New Zealand Dialysis and Transplant Registry data. All patients treated at participating peritoneal dialysis centres received the allocated treatment.Fig. 1Flow of clusters and participants from enrolment to analysis.Some content adapted from https://doi.org/10.1186/s12882-025-04440-5 with permission. Flow of clusters and participants from enrolment to analysis. Procedures The standardised curriculum was based on the “ISPD Syllabus for Teaching Peritoneal Dialysis to Patients and Caregivers” published in 20169 and developed collaboratively by The HOME Network,12 the Australasian Kidney Trials Network, education experts, eLearning developers, and consumer partners.13 A feasibility study assessed the acceptability and usability of the materials, and subsequent process evaluation interviews informed further refinement.14,15 Dialysis centres assigned to the Usual Care continued their usual peritoneal dialysis training practices, which were locally developed and varied considerably across centres. This patient training typically involved face-to-face instruction delivered by nurse trainers over several days, with sessions of 1–3 h. Training content generally covered core topics such as hand hygiene, aseptic technique, bag exchange procedures, exit-site care, recognition of complications (e.g., peritonitis), and emergency protocols. Teaching methods commonly included demonstration and verbal instruction using locally produced, printed materials, with limited use of standardised adult learning principles or competency checklists. Assessment of patient readiness was usually informal and based on observation rather than structured evaluation. Retraining and caregiver involvement were handled according to local policy and resources. Data collection Participant demographic and clinical data were collected routinely in the Australia and New Zealand Dialysis and Transplant Registry and in the New Zealand Peritoneal Dialysis Registry.10 Data for quality of life were collected in a purpose-built Research Electronic Data Capture (REDCap) database16,17 using the European Quality of Life 5 Dimensions 5 Level health survey. Outcomes The primary outcome was time from first day of peritoneal dialysis training to the first peritoneal dialysis-related infection (exit-site infection, tunnel infection, or peritonitis) occurring up to 2 years after commencement of training. Peritoneal dialysis-related infection is considered the topmost critically important core outcome by patients, carers and clinicians according to the Standardised Outcomes in Nephrology (SONG)-PD initiative18 and the ISPD has issued guidelines for prevention of both peritonitis19 and PD catheter-related infection,20 which include low certainty evidence recommendations on training programmes. Exit site infection, tunnel infections, and peritonitis were defined according to ISPD criteria.19,20 The secondary outcomes were the first occurrence of each individual component of the primary outcome, infection-related peritoneal dialysis catheter removal, transfer to haemodialysis for greater than 30 days and 180 days, all-cause death, and quality of life. These outcomes and analyses were prespecified.10,11 Ethics All TEACH-PD participants provided written and informed consent prior to the commencement of any research activities. Approval for this study was granted by the South Western Sydney Local Health District Human Research Ethics Committee (AU/1/970A317) in Australia and the Northern B Health and Disability Ethics Committee (19/NTB/133) in Aotearoa New Zealand. We confirm that all methods were performed in accordance with the relevant guidelines and regulations. This study did not include the use of tissue samples. The patient information and consent forms were approved by a responsible Independent Ethics Committee with jurisdiction for the participating cluster prior to the beginning of the trial at that cluster. Eligible participants were presented with the participant information sheet and consent form outlining the purpose and design of the trial. ANZDATA provided de-identified, aggregated data for patients who commenced PD during the trial recruitment period. ANZDATA had ethical approval from the Royal Adelaide Hospital Human Research Ethics Committee (approval number HREC/17/RAH/408R20170927) through to 29 November 2027. The TEACH-PD trial was registered on 24 January 2019 (ClinicalTrials.gov NCT03816111). This study was conducted in accordance with the principles of the Declaration of Helsinki, and all procedures involving human participants adhered to established ethical standards. Statistical analysis Assuming an incidence of peritoneal dialysis-related infection within the 2 years of the study of 47%, 80% statistical power, an intra-cluster correlation coefficient of 0.001, and a two-sided type 1 error of 0.05, we calculated that approximately 1500 participants would be needed in at least 42 clusters to detect a 20% reduction in the hazard rate of the primary outcome.10,11 Losses to follow-up (withdrawals, etc.) were not considered in the sample size calculations due to the time-to-event nature of the analysis, which considers losses by censoring (Supplementary Figure S1). The analysis of the primary outcome was an intention-to-treat comparison of the primary outcome in the Standardised Training and Usual Care groups modelled as clustered survival data with competing risks (death, transplant, haemodialysis transfer; Supplementary Figure S2) using a marginal, multistate, Cox regression model with robust sandwich variance estimator and adjustments for cluster size, country, and their interaction.11,21 Potentially informative censoring events (e.g., withdrawal of consent, physician's decision to withdraw, transfer to a non-participating peritoneal dialysis centre, loss to follow up) were assessed with sensitivity analysis. Exploratory analyses adjusted the primary model for cluster- and participant-level characteristics. Proportional hazards assumptions (global and transition-specific) were tested. All consented participants were included in the analysis. There were no interim analyses or pre-specified rules for early stopping. The DSMB met approximately 6 monthly to review the trial progress and safety outcomes. Secondary outcomes were analysed similarly. Transfer to haemodialysis was analysed with generalised linear models fit via generalised estimating equations. Mortality was analysed using Cox regression; quality of life was analysed using mixed-effects linear regression. All models were adjusted for factors used in the primary model. Linear regression assumptions were checked via residual normality, homoscedasticity, and residual-fitted value patterns. Since registry data were complete for the primary and most secondary analyses, no methods were required to handle missing data. Intra-cluster correlation coefficients, incidence rates, and rate ratios were calculated. Kaplan-Meier survival estimates and the cumulative incidence function for the primary outcome were graphed. Descriptive statistics were repeated with stratification by sex in accordance with the SAGER guidelines.22 All analyses were completed using version-controlled R v4.4.0 (R Foundation for Statistical Computing). Role of the funding source The TEACH-PD trial received funding from national and international agencies and organisations, industry partners, and fellowships supporting individual investigators. The funders had no involvement in study design, data collection, data analyses, data interpretation, or the writing of the manuscript. Results Sites A total of 68 dialysis centres were assessed for eligibility, of which 54 were eligible, and 42 were enrolled and underwent randomisation. The CONSORT flow diagram (Fig. 1) and are presented, and dialysis centre characteristics are provided in Supplementary Table S1. Patients Between 22 July 2019 and 29 September 2023, 2644 patients were assessed for eligibility, of whom 1462 (55%) were enrolled. The mean age was 59 years, 64% were male, and 44% had diabetes (Table 1). Overall, 667 patients were assigned to Standardised Training group and 795 were assigned to the Usual Care (Fig. 1). The two randomised groups were well balanced with respect to sex and gender (Supplementary Table S2 and Supplementary Table S3).Table 1Participant characteristics at baseline.Usual careN = 795Standardised trainingN = 667TotalN = 1462Age (years)a59.0 ± 15.659.5 ± 15.859.2 ± 15.7Sex: Male499/795 (62.8)432/667 (64.8)931/1462 (63.7) Female296/795 (37.2)235/667 (35.2)531/1462 (36.3)Ethnicity: European507/791 (64.1)319/659 (48.4)826/1450 (57.0) Asian95/791 (12.0)118/659 (17.9)213/1450 (14.7) New Zealand Māori54/791 (6.8)70/659 (10.6)124/1450 (8.6) Pasifika53/791 (6.7)43/659 (6.5)96/1450 (6.6) Indian36/791 (4.6)28/659 (4.2)64/1450 (4.4) Aboriginal/Torres Strait Islander22/791 (2.8)26/659 (4.0)48/1450 (3.3) African18/791 (2.3)20/659 (3.0)38/1450 (2.6) Arab3/791 (0.4)27/659 (4.1)30/1450 (2.1) Other3/791 (0.4)8/659 (1.2)11/1450 (0.8)Country: Australia628/795 (79.0)478/667 (71.7)1106/1462 (75.6)Cluster size category: Small65/795 (8.2)46/667 (6.9)111/1462 (7.6) Medium202/795 (25.4)188/667 (28.2)390/1462 (26.7) Large187/795 (23.5)166/667 (24.9)353/1462 (24.1) Very large341/795 (42.9)267/667 (40.0)608/1462 (41.6)Current smoker85/795 (10.7)74/667 (11.1)159/1462 (10.9)Body mass index (kg/m2)a28.2 ± 6.028.0 ± 6.728.1 ± 6.4Serum creatinine (μmol/L)a686 ± 301658 ± 261674 ± 283Primary kidney disease: Diabetes-related nephropathy248/795 (31.2)245/667 (36.7)493/1462 (34) Glomerular disease213/795 (26.8)184/667 (27.6)397/1462 (27) Hypertension/vascular disease81/795 (10.2)85/667 (12.7)166/1462 (11) Familial/hereditary89/795 (11.2)51/667 (7.6)140/1462 (9.6) Tubulointerstitial71/795 (8.9)51/667 (7.6)122/1462 (8.3) Other systemic disease93/795 (11.7)51/667 (7.6)144/1462 (9.9)Chronic lung disease75/795 (9.4)65/667 (9.7)140/1462 (9.6)Coronary artery disease189/795 (23.8)164/667 (24.6)353/1462 (24.1)Peripheral vascular disease98/795 (12.3)111/667 (16.6)209/1462 (14.3)Cerebrovascular disease60/795 (7.5)64/667 (9.6)124/1462 (8.5)History of cancer93/795 (11.7)81/667 (12.1)174/1462 (11.9)Diabetes321/795 (40.4)319/667 (47.8)640/1462 (43.8)Treatment: CAPD539/794 (67.9)463/667 (69.4)1002/1461 (68.6) APD/IPD255/794 (32.1)204/667 (30.6)459/1461 (31.4)Values presented as n/N (%) or mean ± standard deviation.APD = automated peritoneal dialysis; CAPD = continuous ambulatory peritoneal dialysis; IPD = intermittent peritoneal dialysis.aNo missing values. Table 1Participant characteristics at baseline.Usual careN = 795Standardised trainingN = 667TotalN = 1462Age (years)a59.0 ± 15.659.5 ± 15.859.2 ± 15.7Sex: Male499/795 (62.8)432/667 (64.8)931/1462 (63.7) Female296/795 (37.2)235/667 (35.2)531/1462 (36.3)Ethnicity: European507/791 (64.1)319/659 (48.4)826/1450 (57.0) Asian95/791 (12.0)118/659 (17.9)213/1450 (14.7) New Zealand Māori54/791 (6.8)70/659 (10.6)124/1450 (8.6) Pasifika53/791 (6.7)43/659 (6.5)96/1450 (6.6) Indian36/791 (4.6)28/659 (4.2)64/1450 (4.4) Aboriginal/Torres Strait Islander22/791 (2.8)26/659 (4.0)48/1450 (3.3) African18/791 (2.3)20/659 (3.0)38/1450 (2.6) Arab3/791 (0.4)27/659 (4.1)30/1450 (2.1) Other3/791 (0.4)8/659 (1.2)11/1450 (0.8)Country: Australia628/795 (79.0)478/667 (71.7)1106/1462 (75.6)Cluster size category: Small65/795 (8.2)46/667 (6.9)111/1462 (7.6) Medium202/795 (25.4)188/667 (28.2)390/1462 (26.7) Large187/795 (23.5)166/667 (24.9)353/1462 (24.1) Very large341/795 (42.9)267/667 (40.0)608/1462 (41.6)Current smoker85/795 (10.7)74/667 (11.1)159/1462 (10.9)Body mass index (kg/m2)a28.2 ± 6.028.0 ± 6.728.1 ± 6.4Serum creatinine (μmol/L)a686 ± 301658 ± 261674 ± 283Primary kidney disease: Diabetes-related nephropathy248/795 (31.2)245/667 (36.7)493/1462 (34) Glomerular disease213/795 (26.8)184/667 (27.6)397/1462 (27) Hypertension/vascular disease81/795 (10.2)85/667 (12.7)166/1462 (11) Familial/hereditary89/795 (11.2)51/667 (7.6)140/1462 (9.6) Tubulointerstitial71/795 (8.9)51/667 (7.6)122/1462 (8.3) Other systemic disease93/795 (11.7)51/667 (7.6)144/1462 (9.9)Chronic lung disease75/795 (9.4)65/667 (9.7)140/1462 (9.6)Coronary artery disease189/795 (23.8)164/667 (24.6)353/1462 (24.1)Peripheral vascular disease98/795 (12.3)111/667 (16.6)209/1462 (14.3)Cerebrovascular disease60/795 (7.5)64/667 (9.6)124/1462 (8.5)History of cancer93/795 (11.7)81/667 (12.1)174/1462 (11.9)Diabetes321/795 (40.4)319/667 (47.8)640/1462 (43.8)Treatment: CAPD539/794 (67.9)463/667 (69.4)1002/1461 (68.6) APD/IPD255/794 (32.1)204/667 (30.6)459/1461 (31.4)Values presented as n/N (%) or mean ± standard deviation.APD = automated peritoneal dialysis; CAPD = continuous ambulatory peritoneal dialysis; IPD = intermittent peritoneal dialysis.aNo missing values. Participant characteristics at baseline. Values presented as n/N (%) or mean ± standard deviation. APD = automated peritoneal dialysis; CAPD = continuous ambulatory peritoneal dialysis; IPD = intermittent peritoneal dialysis. No missing values. Primary outcome A peritoneal dialysis-related infection within the 2 years of the study occurred in 296 of 667 patients (44%) in Standardised Training and 297 of 795 patients (37%) in Usual Care log-rank test p = 0.012; sub-hazard ratio [sHR] 1.230 (95% CI 1.004–1.507, p = 0.0457) (Fig. 2, Table 2, Supplementary Table S4). The incidence rate (IR) per person-year was 0.41 (95% CI 0.37–0.46) in Standardised Training and 0.34 (95% CI 0.30–0.38) in Usual Care, with an incidence rate ratio (IRR) of 1.23 (95% CI 1.05–1.45). Sensitivity and exploratory analyses demonstrated similar results (Supplementary Table S4), while the intra-cluster correlation was considerably greater than anticipated (Supplementary Table S5). Divergence in peritoneal dialysis-related infection risk between groups occurred early after PD initiation (Supplementary Figure S3).Fig. 2Kaplan–Meier estimates of the probability of remaining free from infection. Shaded areas represent 95% confidence intervals. Std. = standardised.Table 2Trial outcomes.Usual CareStandardised TrainingEffect sizeN = 795N = 667TypeEstimate (95% CI)Total follow-up (person-years)887717––Primary outcome297/795 (37.4)296/667 (44.4)sHR1.23 (1.004–1.51) Incidence rate (per person-year)0.34 (0.30–0.38)0.41 (0.37–0.46)IRR1.23 (1.05–1.45)Exit site infection99/795 (12.5)117/667 (17.5)sHR1.40 (0.89–2.21) Incidence rate (per person-year)0.09 (0.08–0.11)0.13 (0.11–0.16)IRR1.43 (1.09–1.89)Tunnel infection19/795 (2.4)9/667 (1.3)sHR0.49 (0.18–1.29) Incidence rate (per person-year)0.02 (0.01–0.03)0.01 (0.004–0.02)IRR0.54 (0.22–1.26)Peritonitis230/795 (28.9)227/667 (34.0)sHR1.19 (0.97–1.46) Incidence rate (per person-year)0.24 (0.21–0.27)0.28 (0.24–0.31)IRR1.17 (0.97–1.41)Infection-associated catheter removal81/795 (10.2)75/667 (11.2)sHR1.11 (0.86–1.43) Incidence rate (per person-year)0.07 (0.06–0.09)0.08 (0.06–0.10)IRR1.07 (0.78–1.49)Transfer to HD (>30 days)317/795 (39.9)267/667 (40.0)OR1.01 (0.81–1.26)Transfer to HD (>180 days)257/795 (32.3)224/667 (33.6)OR1.05 (0.84–1.31)Mortality (all-cause)86/795 (10.8)75/667 (11.2)HR0.94 (0.68–1.30)EQ-5D-5L index score (at 2 years)0.862 ± 0.1960.852 ± 0.205eMD0.010 (−0.018–0.038)EQ-5D-5L VAS (at 2 years)73.0 ± 18.372.5 ± 18.7eMD0.4 (−2.6–3.4)Values presented as n/N (%), mean ± standard deviation, or estimate (95% confidence interval); hospitalisation and cost-effectiveness outcomes to be reported in a separate publication.CI = confidence interval; eMD = estimated mean difference; EQ-5D-5L = EuroQol 5-dimension 5-level health-related quality of life score; HR = hazard ratio; IRR = incidence rate ratio; OR = odds ratio; sHR = sub-hazard ratio for the relevant transition (i.e., from trial start to outcome); VAS = visual analogue scale of overall health status. Kaplan–Meier estimates of the probability of remaining free from infection. Shaded areas represent 95% confidence intervals. Std. = standardised. Table 2Trial outcomes.Usual CareStandardised TrainingEffect sizeN = 795N = 667TypeEstimate (95% CI)Total follow-up (person-years)887717––Primary outcome297/795 (37.4)296/667 (44.4)sHR1.23 (1.004–1.51) Incidence rate (per person-year)0.34 (0.30–0.38)0.41 (0.37–0.46)IRR1.23 (1.05–1.45)Exit site infection99/795 (12.5)117/667 (17.5)sHR1.40 (0.89–2.21) Incidence rate (per person-year)0.09 (0.08–0.11)0.13 (0.11–0.16)IRR1.43 (1.09–1.89)Tunnel infection19/795 (2.4)9/667 (1.3)sHR0.49 (0.18–1.29) Incidence rate (per person-year)0.02 (0.01–0.03)0.01 (0.004–0.02)IRR0.54 (0.22–1.26)Peritonitis230/795 (28.9)227/667 (34.0)sHR1.19 (0.97–1.46) Incidence rate (per person-year)0.24 (0.21–0.27)0.28 (0.24–0.31)IRR1.17 (0.97–1.41)Infection-associated catheter removal81/795 (10.2)75/667 (11.2)sHR1.11 (0.86–1.43) Incidence rate (per person-year)0.07 (0.06–0.09)0.08 (0.06–0.10)IRR1.07 (0.78–1.49)Transfer to HD (>30 days)317/795 (39.9)267/667 (40.0)OR1.01 (0.81–1.26)Transfer to HD (>180 days)257/795 (32.3)224/667 (33.6)OR1.05 (0.84–1.31)Mortality (all-cause)86/795 (10.8)75/667 (11.2)HR0.94 (0.68–1.30)EQ-5D-5L index score (at 2 years)0.862 ± 0.1960.852 ± 0.205eMD0.010 (−0.018–0.038)EQ-5D-5L VAS (at 2 years)73.0 ± 18.372.5 ± 18.7eMD0.4 (−2.6–3.4)Values presented as n/N (%), mean ± standard deviation, or estimate (95% confidence interval); hospitalisation and cost-effectiveness outcomes to be reported in a separate publication.CI = confidence interval; eMD = estimated mean difference; EQ-5D-5L = EuroQol 5-dimension 5-level health-related quality of life score; HR = hazard ratio; IRR = incidence rate ratio; OR = odds ratio; sHR = sub-hazard ratio for the relevant transition (i.e., from trial start to outcome); VAS = visual analogue scale of overall health status. Trial outcomes. Values presented as n/N (%), mean ± standard deviation, or estimate (95% confidence interval); hospitalisation and cost-effectiveness outcomes to be reported in a separate publication. CI = confidence interval; eMD = estimated mean difference; EQ-5D-5L = EuroQol 5-dimension 5-level health-related quality of life score; HR = hazard ratio; IRR = incidence rate ratio; OR = odds ratio; sHR = sub-hazard ratio for the relevant transition (i.e., from trial start to outcome); VAS = visual analogue scale of overall health status. Secondary outcomes Exit site infection occurred in 117 of 667 patients (18%) in Standardised Training and 99 of 795 patients (12%) in Usual Care (sHR 1.40 [95% CI 0.89–2.21]). Tunnel infection occurred in 9 of 667 patients (1%) in Standardised Training and 19 of 795 patients (2%) in Usual Care (sHR 0.49 [95% CI 0.18–1.29]). Peritonitis occurred in 227 of 667 patients (34%) in Standardised Training and 230 of 795 patients (29%) in Usual Care (sHR 1.19 [95% CI 0.97–1.46]). No significant differences were observed between the groups with respect to infection-associated catheter removal (sHR 1.11 [95% CI 0.86–1.43]), haemodialysis transfer at 30 days (odds ratio [OR] 1.01 [95% CI 0.81–1.26]) and 180 days (OR 1.05 [95% CI 0.84–1.31]), mortality (HR 0.94 [95% CI 0.68–1.30]), and quality of life (estimated mean difference 0.01 [95% CI −0.02–0.04]) (Table 2, Supplementary Table S6, and Supplementary Figures S4–S9). Discussion Among adults commencing peritoneal dialysis in this bi-national cluster-randomised controlled trial, the ISPD clinical practice guideline-based standardised peritoneal dialysis training curriculum for trainers and patients was associated with a significantly increased risk of peritoneal dialysis-related infections compared with usual care. This finding demonstrates that training practices are important for the outcomes of patients commencing peritoneal dialysis. The study results contribute to a limited body of evidence related to training interventions in peritoneal dialysis.7,23 Prior studies of incident training have been non-randomised and suggested that training programs based on adult learning principles may be associated with reduced peritonitis rates, although detailed descriptions of program contents and structure were not provided.24,25 Four randomised controlled trials showed that refresher training after incident training reduced peritoneal dialysis infections.7,23 The reasons for differences in infection outcomes after initial and subsequent training on peritoneal dialysis outcomes are unclear, as patient training is a complex intervention and outcomes in different trials may relate to variations in clinical settings, curricula, learning principles, clinician practices/training, and implementation. The results of the present trial remained consistent after adjustments for patient- and cluster-level characteristics, suggesting that the observed differences were not attributable to factors pre-specified in the statistical analysis plan such as centre characteristics, imbalances in participant characteristics (ethnicity, serum creatinine, primary kidney disease, diabetes, and peripheral vascular disease), and censoring events. A formal process evaluation is needed to explore how the intervention was implemented across sites, and whether fidelity, engagement, or contextual factors may have influenced the effects of the standardised curriculum. We hypothesise several potential explanatory factors for the observed increase in infections with an ISPD clinical practice guideline-based standardised curriculum. The implementation of a new training practice for nurse trainers and patients required a change in a core clinical practice at dialysis centres that was different from usual care previously established in the context of local workflows, expertise, and patient populations. Transitioning to a new methodology may have temporarily disrupted established routines and reduced training efficiency during the early phase of adoption. However, the persistent effect of increased infections with the standardised curriculum across 2 years is not consistent with this hypothesis. While standardisation may improve healthcare consistency and quality, it may not fully accommodate individual circumstances and learning requirements of patients or nurse trainers. Personalisation is a key component of effective education, particularly in chronic disease management.26,27 The standardised curriculum was designed based on educational best practices and adult learning principles to support learner motivation and adoption.14 It is possible that the curriculum did not sufficiently support clinicians in adapting their practices to accommodate the cognitive, cultural, or psychosocial factors that influence patient learning and retention of peritoneal dialysis techniques, and that elements of the training program such as its volume, pacing, or delivery format, were not optimally aligned with adult learning principles or conducive to long-term mastery of a safe technique. Finally, the COVID-19 pandemic significantly impacted healthcare delivery during the trial period. Delays in rolling out the TEACH-PD intervention, disruptions to staffing and training schedules, and increased reliance on remote or modified education formats might have affected the consistency and effectiveness of training. Importantly, effect patterns appeared consistent across study periods, including during the peak COVID-19 disruptions. While pandemic-related factors may plausibly influence training fidelity, our additional analyses render a substantial COVID-effect unlikely; nevertheless, this hypothesis cannot be entirely excluded, and any consistent or divergent patterns of effect should be interpreted with this caveat in mind. No differences were observed between the two groups with respect to any of the secondary outcomes, including individual components of the primary outcome. It should be noted that the study was not powered for these secondary outcomes and that event rates were lower than for the composite primary outcome. Consequently, the possibility of a type 2 statistical error cannot be excluded. The strengths of the trial include its pragmatic design, which enabled broad participation across dialysis centres and supported the inclusion of patient characteristics that were highly representative of the Australia and New Zealand peritoneal dialysis population, as demonstrated in our baseline analysis.28 The pragmatic design also allowed evaluation of the effectiveness of the training intervention in real-life routine practice settings. Recruitment targets for both clusters and participants were achieved,11 and the intervention was based on the ISPD clinical practice guidelines.9,13 In addition, the incidence of the primary outcome was sufficient to provide definitive evidence regarding the effect of peritoneal dialysis training on serious infections. Balanced against these strengths, the study had several limitations. Clinicians at participating centres were aware of their trial group assignment, which may have impacted assessments of infection (detection bias) and treatment decisions (performance bias). However, blinding was not feasible given the educational nature of the intervention. To minimise bias, objective and standardised definitions for PD-related infections were applied, and statistical analyses were masked to treatment allocation during initial analyses. This study was designed as a large-scale pragmatic trial aiming for diverse populations, high generalisability and minimal disruption to routine care. Consequently, aspects of PD care other than PD training, such as catheter insertion techniques, break-in periods, exit-site care, dressing practices, PD consumables and home visits, were delivered according to usual local practices, were heterogeneous and were not standardised by protocol. Data on these diverse practices were not collected, and variation in centre-specific practices may have influenced infection outcomes. While this limits mechanistic interpretation, it strengthened external validity by reflecting real-world PD care. Data were obtained from the ANZDATA Registry; although previous evaluations of registry data quality have shown good concordance with hospital administrative datasets,29 the possibility of coding bias could not be excluded. Delays in rolling out the TEACH-PD standardised training intervention led to a smaller number of patients in the standardised training group (667 vs 795 patients) which could have potentially biased results in favour of the null hypothesis and reduced the estimate of effect. The trial excluded approximately one-third of eligible patients, who may have had different clinical and demographic characteristics. The findings were robust after adjustment for pre-specified patient and centre characteristics. We previously found that the demographic and clinical characteristics of patients who participated in the trial were similar to those of Australian and New Zealand patients who did not participate in the trial during the trial recruitment period.28 Investigation of the relatively high centre-level differences in infection rates (resulting in a higher than expected intra-cluster correlation) was outside of the scope of the trial. Our trial was conducted in Australia and New Zealand, so the results may not inform practices in other global regions. The findings of this trial showed that, among adult patients commencing peritoneal dialysis, the use of a standardised training curriculum for trainers and patients guided by the ISPD clinical practice guidelines increased peritoneal dialysis-related infection over 2 years of follow-up. While standardised training should provide an essential foundation for the practice of peritoneal dialysis, it might not be sufficient to improve clinical outcomes in isolation. Future PD education strategies should move towards hybrid models that combine standardised core competencies with flexibility for local practice, patient characteristics and ongoing personalised reinforcement. Implementation-focused research is needed to identify which elements of training require standardisation and where individualisation is most beneficial to support safe, sustainable and patient-centred peritoneal dialysis care. Contributors JSFC—Literature search, study design and conceptualisation, data interpretation, led manuscript writing, funding acquisition; Global Principal Chief Investigator. NB—Literature search, study design and conceptualisation, data interpretation, led manuscript writing, funding acquisition; Global Principal Chief Investigator. SG—Study design and conceptualisation, data interpretation, led manuscript writing, funding acquisition; Aotearoa New Zealand Chief Investigator. YC—Literature search, study design and conceptualisation, data interpretation, led manuscript writing, funding acquisition. GM—Formal data analysis and writing. JK—Formal data analysis and writing. RC—Study design and conceptualisation, project administration. HC—Project administration and data follow up. CH—Supervision, study design and conceptualisation. LH—Study design and conceptualisation, project administration. CK—Study data follow up, project administration. MM—Study data follow up, project administration. RM—Project administration and data follow up. EP—Study design and conceptualisation. DR—Project administration and resource. AV—Project administration and data follow up. PV—Study data follow up, project administration. LV—Literature search, funding acquisition, project administration and data follow up. CA—Project administration and data follow up. BB—Study design and member of Global Steering Committee. KE—Study design and member of Global Steering Committee. AEF—Study design and member of Global Steering Committee. TF—Study design and member of Global Steering Committee. RH—Study data follow up and project administration. AH—Study design and member of Global Steering Committee. KH—Study design and lead healthcare resource analysis. MH—Study design and lead healthcare resource analysis. AJ—Study design and member of Global Steering Committee. MJ—Study design and member of Global Steering Committee. AL—Study design and member of Global Steering Committee. SSM—Project administration and study procedure follow up. JM—Study design and member of Global Steering Committee. TN—Study design and member of Global Steering Committee. WS—Study design and member of Global Steering Committee. GZSL—Study design and member of Global Steering Committee. MT—Study procedure follow up, study design and member of Global Steering Committee. MU—Study design and member of Global Steering Committee. DV—Study design and member of Global Steering Committee. RCW—Study design and member of Global Steering Committee. DWJ—Supervision, study design and conceptualisation, data interpretation, led manuscript writing, funding acquisition. All authors contributed to revising the manuscript and read and approved the final version of the manuscript. All authors confirmed that they had full access to all the data in the study and accepted responsibility to submit for publication. DWJ and YC accessed and verified the underlying data. Collaborative authors contributed to recruitment, data collection and follow up of study participants. Data sharing statement De-identified individual participant data underlying the findings in this publication will be made available by the sponsor in a designated repository for external researchers. Supporting files, including metadata (data dictionary, codebook, and case report forms) and statistical programs from the main analysis, will also be accessible alongside the datasets. The Statistical Analysis Plan and Study Protocol are publicly available on the sponsor's website (https://aktn.org.au/). External researchers may submit data-sharing proposals, which will be reviewed by a Data Access Committee–a designated board responsible for evaluating requests based on scientific merit, benefit-risk assessment, and research team expertise. Approved proposals will receive access to the relevant data starting two years after the publication of the main trial results. Requests for data sharing beyond five years after publication will be considered; however, the level of investigator support provided will depend on the ongoing capacity of the data access team. Declaration of interests JSFC has previously received speaker's honoraria and research funds from Baxter Healthcare, Fresenius Medical Care, Roche Pharmaceuticals, Amgen and Vantive. NB has received research funding support from Amgen, NHMRC, and HRC NZ; honoraria from Vantive and Therapeutic Guidelines and payment as an expert witness for the WA Coronial Police. YC has received speaker's honoraria and research grants from Vantive (Baxter) Healthcare and Fresenius Medical Care. She is a Medical Advisory Board member of Asia Pacific Region Fresenius Medical Care. AEF has received consulting fees from Bayer, speaker's honoraria from Vantive and holds leadership role with ISPD and ISN. Walaa W M Saweirs has speaker's honoraria from Vantive (Baxter) Healthcare. GZSL is affiliated with NICM Health Research Institute, which receives untied research grants and donations from foundations, universities, government agencies, individuals, and industry to advance the vision and mission of the Institute. RCW has previously received speaker's honoraria and research funds from Baxter Healthcare. The project that is the subject of this article was not undertaken as part of a contractual relationship with any organisation other than the funding declared. All other authors declare no competing interests.